{
    "root": "6c4547c4-9429-42e5-998f-e97f6a74f150",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250327",
    "ingredients": [
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        }
    ],
    "indications": "rosuvastatin tablets indicated : reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk ( cv ) disease based age , high-sensitivity c-reactive protein ( hscrp ) \u22652 mg/l , least one additional cv risk factor . adjunct diet : reduce low-density lipoprotein cholesterol ldl-c adults primary hyperlipidemia . reduce ldl-c slow progression atherosclerosis adults . reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
    "contraindications": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin modifications due . ( 2.6 )",
    "warningsAndPrecautions": "rosuvastatin tablets supplied : strength supplied ndc tablet description 5 mg bottles 90 tablets bottles 500 tablets bottles 1000 tablets ndc 27808-155-01 ndc 27808-155-03 ndc 27808-155-02 pink , round , biconvex , coated tablets . debossed \u2018 cy \u2019 one side \u2018 5 \u2019 side 10 mg bottles 90 tablets bottles 500 tablets bottles 1000 tablets ndc 27808-156-01 ndc 27808-156-03 ndc 27808-156-02 yellow , round , biconvex , coated tablets . debossed \u2018 cy \u2019 one side , \u2018 10 \u2019 side 20 mg bottles 90 tablets bottles 500 tablets bottles 1000 tablets ndc 27808-157-01 ndc 27808-157-03 ndc 27808-157-02 yellow , round , biconvex , coated tablets . debossed \u2018 cy \u2019 one side , \u2018 20 \u2019 side 40 mg bottles 30 tablets bottles 500 tablets bottles 1000 tablets ndc 27808-158-01 ndc 27808-158-03 ndc 27808-158-02 pink , round , biconvex , coated tablet . debossed \u2018 cy \u2019 one side , \u2018 40 \u2019 side storage store controlled room temperature , 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "rosuvastatin tablets contraindicated following conditions : acute liver failure decompensated cirrhosis [ w arnings ( 5.3 ) ] . hypersensitivity rosuvastatin excipients rosuvastatin tablets . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin tablets [ dverse ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets is indicated:\n                  \n                     To reduce the risk of major adverse cardiovascular (CV) events (CV\u00a0death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of (CV) disease based on age, high-sensitivity C-reactive protein (hsCRP) \u22652 mg/L, and at least one additional CV risk factor.\n                     As an adjunct to diet to:\n                  \n                  \n                     Reduce low-density lipoprotein cholesterol LDL-C in adults with primary hyperlipidemia.\n                     Reduce LDL-C and slow the progression of atherosclerosis in adults.\n                     Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                  \n                  \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\n                  \n                  \n                     As an adjunct to diet for the treatment of adults with:\n                  \n                  \n                     Primary dysbetalipoproteinemia.\n                     Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. (2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. (2.1) Adults: Recommended dosage range is 5 to 40 mg once daily. (2.1) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. (2.2) Pediatric Patients with HoFH : Recommended dosage is 20 mg once daily for patients aged 7 years and older. (2.2) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. (2.4) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. (2.5 ) See full prescribing information for rosuvastatin dosage and administration modifications due to drug interactions. (2.6)",
    "warningsAndPrecautions_original": "Rosuvastatin tablets are supplied as:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 How Supplied\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              5 mg\n                           \n                           \n                              bottles of 90 tablets\n                              bottles of 500 tablets\n                              bottles of 1000 tablets\n                           \n                           \n                              NDC 27808-155-01\n                              NDC 27808-155-03\n                              NDC 27808-155-02\n                           \n                           \n                              Pink, round, biconvex, coated tablets. Debossed as \u2018CY\u2019 on one side and \u20185\u2019 on other side\n                           \n                        \n                        \n                           \n                              10 mg\n                           \n                           \n                              bottles of 90 tablets\n                              bottles of 500 tablets\n                              bottles of 1000 tablets\n                           \n                           \n                              NDC 27808-156-01\n                              NDC 27808-156-03\n                              NDC 27808-156-02\n                           \n                           \n                              Yellow, round, biconvex, coated tablets. Debossed as \u2018CY\u2019 on one side, and \u201810\u2019 on other side\n                           \n                        \n                        \n                           \n                              20 mg\n                           \n                           \n                              bottles of 90 tablets\n                              bottles of 500 tablets\n                              bottles of 1000 tablets\n                           \n                           \n                              NDC 27808-157-01\n                              NDC 27808-157-03\n                              NDC 27808-157-02\n                           \n                           \n                              Yellow, round, biconvex, coated tablets. Debossed as \u2018CY\u2019 on one side, and \u201820\u2019 on other side\n                           \n                        \n                        \n                           \n                              40 mg\n                           \n                           \n                              bottles of 30 tablets\n                              bottles of 500 tablets\n                              bottles of 1000 tablets\n                           \n                           \n                              NDC 27808-158-01\n                              NDC 27808-158-03\n                              NDC 27808-158-02\n                           \n                           \n                              Pink, round, biconvex, coated tablet. Debossed as \u2018CY\u2019 on one side, and \u201840\u2019 on other side\n                           \n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Rosuvastatin tablets is contraindicated in the following conditions:\n                  \n                     Acute liver failure or decompensated cirrhosis [see \n                        \n                           \n                              W\n                           \n                           \n                              arnings and Precautions (5.3)\n                           \n                        \n                        ].\n                     \n                     Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets [\n                        see \n                        \n                           \n                              A\n                           \n                           \n                              dverse Reactions (6.1)\n                           \n                        \n                        ]."
}